Ocugen, Inc. (NASDAQ:OCGN) Shares Bought by Jane Street Group LLC

Jane Street Group LLC increased its holdings in Ocugen, Inc. (NASDAQ:OCGN - Free Report) by 258.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 496,177 shares of the company's stock after acquiring an additional 357,891 shares during the quarter. Jane Street Group LLC owned approximately 0.17% of Ocugen worth $399,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Ocugen in the fourth quarter worth about $32,000. Tower Research Capital LLC TRC lifted its stake in Ocugen by 309.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company's stock valued at $32,000 after buying an additional 30,120 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Ocugen during the fourth quarter valued at $40,000. Two Sigma Securities LLC grew its position in shares of Ocugen by 92.9% during the fourth quarter. Two Sigma Securities LLC now owns 51,909 shares of the company's stock worth $42,000 after acquiring an additional 25,004 shares during the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management acquired a new stake in shares of Ocugen in the 4th quarter worth about $56,000. Hedge funds and other institutional investors own 10.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Chardan Capital reissued a "buy" rating and set a $7.00 target price on shares of Ocugen in a research note on Monday, May 12th. HC Wainwright cut their price target on Ocugen from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Monday, May 12th.

Ocugen Stock Performance

Shares of NASDAQ OCGN traded up $0.04 during midday trading on Wednesday, reaching $0.89. 3,449,012 shares of the company traded hands, compared to its average volume of 4,476,312. The company has a market cap of $259.09 million, a price-to-earnings ratio of -4.93 and a beta of 4.21. The stock has a 50-day moving average price of $0.74 and a 200 day moving average price of $0.75. Ocugen, Inc. has a 52 week low of $0.52 and a 52 week high of $1.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The firm had revenue of $1.48 million for the quarter. Sell-side analysts anticipate that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.